Novo Nordisk information

Novo Nordisk A/S
	The Novo Nordisk logo, a bull with a sun disk between his horns, is based on the Egyptian deity Apis.
	Headquarters in Bagsværd, Denmark
Company type	Public
Traded as	Nasdaq Copenhagen: NOVO B; OMX Copenhagen 25 component; NYSE: NVO;
Industry	Pharmaceuticals, Health care
Founded	21 December 1923; 100 years ago
Headquarters	Bagsværd, Denmark
Key people	Helge Lund (Chairman); Lars Fruergaard Jørgensen (president and CEO);
Products	Ozempic; Ryzodeg; Victoza; NovoEight; Activella; Novolin; Levemir; NovoSeven; Norditropin; Tresiba; Xultophy; NovoRapid; Fiasp; Saxenda;
Revenue	232.3 billion kr. (2023)
Operating income	102.6 billion kr. (2023)
Net income	83.68 billion kr. (2023)
Total assets	314.5 billion kr. (2023)
Total equity	106.6 billion kr. (2023)
Owner	Novo Holdings A/S (28%)
Number of employees	64,319 (end 2023)
Website	novonordisk.com
	Footnotes / references;

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd^[3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.^[4]

Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices.^[5] Its main product is the drug semaglutide, used to treat diabetes under the brand name Ozempic and obesity under the brand name Wegovy.^[6] Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.^[1]

Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries.^[7] The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).^[8]

The company was ranked 25th among the 100 Best Companies to Work For in 2010 and 72nd in 2014 by Fortune.^[9] In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth.^[10] Novo Nordisk is the largest pharmaceutical company in Denmark.^[11] Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued pharmaceutical company in Europe.^[12]

^ ^a ^b "Annual Report 2023" (PDF). Novo Nordisk. Archived from the original (PDF) on 31 January 2024. Retrieved 1 February 2024.
^ "Form 6-K". U.S. Securities and Exchange Commission. 3 August 2022.
^ "Who we are". www.novonordisk.com. Retrieved 28 September 2021.
^ "Novo Nordisk share and ownership structure". Retrieved 24 August 2023.
^ "Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. 5 February 2020. Retrieved 20 April 2020.
^ Nelson, Eshe (30 August 2023). "Novo Nordisk Tilts G.D.P. In Denmark". The New York Times. p. B1. ISSN 0362-4331. Retrieved 5 October 2023.
^ "Annual Report 2021" (PDF). Novo Nordisk. Archived from the original (PDF) on 7 February 2022. Retrieved 13 March 2022.
^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.
^ "100 Best Companies to Work For 2010: Full list". Fortune. 2010.
^ read, Bart King Published 8 years ago About a 2 minute (27 January 2012). "Novo Nordisk Ranked World's Most Sustainable Corporation". Sustainable Brands. Retrieved 20 April 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)
^ Stegger, Clara (2 December 2022). "Første danske virksomhed nogensinde: Novo Nordisk rammer gigantisk beløb". Finans (in Danish). Retrieved 18 January 2023.
^ Wienberg, Christian (9 August 2023). "Novo's Value Surpasses Denmark GDP After Obesity Drug Boost". Bloomberg News.

[AR2023-1] "Annual Report 2023" (PDF). Novo Nordisk. Archived from the original (PDF) on 31 January 2024. Retrieved 1 February 2024.

[2] "Form 6-K". U.S. Securities and Exchange Commission. 3 August 2022.

[:0-3] "Who we are". www.novonordisk.com. Retrieved 28 September 2021.

[4] "Novo Nordisk share and ownership structure". Retrieved 24 August 2023.

[5] "Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. 5 February 2020. Retrieved 20 April 2020.

[nelson20230830-6] Nelson, Eshe (30 August 2023). "Novo Nordisk Tilts G.D.P. In Denmark". The New York Times. p. B1. ISSN 0362-4331. Retrieved 5 October 2023.

[AR2021-7] "Annual Report 2021" (PDF). Novo Nordisk. Archived from the original (PDF) on 7 February 2022. Retrieved 13 March 2022.

[8] "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.

[9] "100 Best Companies to Work For 2010: Full list". Fortune. 2010.

[10] read, Bart King Published 8 years ago About a 2 minute (27 January 2012). "Novo Nordisk Ranked World's Most Sustainable Corporation". Sustainable Brands. Retrieved 20 April 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)

[11] Stegger, Clara (2 December 2022). "Første danske virksomhed nogensinde: Novo Nordisk rammer gigantisk beløb". Finans (in Danish). Retrieved 18 January 2023.

[12] Wienberg, Christian (9 August 2023). "Novo's Value Surpasses Denmark GDP After Obesity Drug Boost". Bloomberg News.

Novo Nordisk information

and 25 Related for: Novo Nordisk information

Novo Nordisk

Novo Nordisk Foundation

Team Novo Nordisk

Semaglutide

The Novo Nordisk Prize

Repaglinide

Lise Kingo

Billy Gardell

Liraglutide

NNIT

Paula Deen

Amycretin

Nordisk

Kasim Kutay

List of largest biomedical companies by revenue

Svetlana Mojsov

ZymoGenetics

Insulin analog

Hans Christian Hagedorn

Novozymes

Insulin degludec

Insulin aspart

Insulin icodec

Helge Lund

Melatonin